The NF-κB Activating Pathways in Multiple Myeloma.

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Multiple myeloma (MM) is the second most common hematological malignancy, characterized by incurable plasma cell cancer.
• Deregulated nuclear factor kappaB (NF-κB) signaling is a key factor in MM pathogenesis.
• Both canonical and non-canonical NF-κB pathways are frequently activated in myeloma cells.

Purpose of the Study:

• To review genetic mutations and microenvironmental factors activating NF-κB in multiple myeloma.
• To elucidate the signaling mechanisms of canonical and non-canonical NF-κB pathways in healthy and malignant cells.
• To discuss the implications of crosstalk between NF-κB pathways in MM.

Main Methods:

• Literature review of genetic mutations and microenvironmental cues in MM.
• Description of NF-κB canonical and non-canonical pathway signaling.
• Analysis of signaling crosstalk and its role in MM.

Main Results:

• NF-κB activation promotes myeloma cell proliferation, survival, and drug resistance.
• Concomitant activation of both NF-κB pathways is a hallmark of MM.
• Signaling crosstalk contributes to aberrant NF-κB activation and pro-survival gene expression in MM.

Conclusions:

• Mechanistic insights into NF-κB deregulation are vital for MM.
• Understanding NF-κB pathways can lead to improved therapeutic strategies for multiple myeloma.
• Targeting NF-κB may offer novel prognostic tools for MM patients.